Tamoxifen
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Take orally 20 mg once daily (or 10 mg twice daily) with water, with or without food. Treatment is typically taken continuously for 5 to 10 years for adjuvant breast cancer therapy.
⚠️ Side Effects
Common: Hot flushes, vaginal discharge, irregular menses, fluid retention, nausea, mood swings. Rare/Severe: Endometrial hyperplasia / endometrial adenocarcinoma, uterine sarcoma, venous thromboembolism (DVT, pulmonary embolism), and stroke.
🛡️ Safety Warnings
Black Box Warning: Increased risk of uterine malignancies (endometrial cancer, uterine sarcoma); promptly evaluate any abnormal vaginal bleeding or pelvic pain in postmenopausal women. Black Box Warning: Venous thromboembolism. Bioactivation requires CYP2D6 to endoxifen; avoid strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion).
Jan Aushadhi Products containing Tamoxifen
Found 2 generic formulation(s) containing this active ingredient.
Tamoxifen Citrate Tablets 10 mg
Tamoxifen Citrate Tablets (10mg, 20mg) is a selective estrogen receptor modulator (SERM) on the WHO Model List of Essential Medicines. In breast tissue, it competitively antagonizes estrogen binding to estrogen receptors (ER), halting ER-mediated transcription and arresting breast tumor cells in the G0/G1 phase. In bone and cardiovascular tissues, it acts as an estrogen agonist (preserving bone density and lipid profiles), but in the endometrium, its partial agonism stimulates endometrial proliferation. Indicated for adjuvant and metastatic treatment of estrogen receptor-positive (ER+) breast cancer in premenopausal and postmenopausal women, ductal carcinoma in situ (DCIS), and breast cancer chemoprevention in high-risk women.
Tamoxifen Citrate Tablets 20 mg
Tamoxifen Citrate Tablets (10mg, 20mg) is a selective estrogen receptor modulator (SERM) on the WHO Model List of Essential Medicines. In breast tissue, it competitively antagonizes estrogen binding to estrogen receptors (ER), halting ER-mediated transcription and arresting breast tumor cells in the G0/G1 phase. In bone and cardiovascular tissues, it acts as an estrogen agonist (preserving bone density and lipid profiles), but in the endometrium, its partial agonism stimulates endometrial proliferation. Indicated for adjuvant and metastatic treatment of estrogen receptor-positive (ER+) breast cancer in premenopausal and postmenopausal women, ductal carcinoma in situ (DCIS), and breast cancer chemoprevention in high-risk women.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Tamoxifen.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Tamoxifen Citrate Tablets 10 mg | 10's | ₹11.34 | MAMOFEN | ₹18.15 | 38% Save |
| Tamoxifen Citrate Tablets 20 mg | 10's | ₹15.86 | MAMOFEN | ₹25.67 | 38% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Tamoxifen generics.